hIL3-hCSF2-Tg(NMG)

Nomenclature

NOD-PrkdcscidIl2rgem1Tg(hIL3-hCSF2)Smoc

Cat. NO.

NM-KI-215006

Strain State

Sperm cryopreservation

Export PDF

Model Description

These transgenic mice carry humanized IL3 and humanized CSF2.

Validation Data

image.png

Fig.1 Detection of hCSF2(A) and hIL3(B) expression in serum by ELISA(n=3). 

Abbr. HO, homozygous; N.D. not detected.

image.png

Fig. 2 Human immune cell phenotyping in hIL3-hCSF2-transgenic (NMG) engrafted with human HSCs. Human CD34+ cells (1.0×10^5) were intravenously injected into homozygous hIL3-hCSF2-transgenic (NMG) pretreated with 1.0 Gy irradiation. These results demonstrate successful engraftment and propagation of human T, B, Myeloid and Momocytescells in the hIL3-hCSF2-transgenic (NMG) model.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more